Skip to product information
1 of 1

  • Images are for illustration purposes only
  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Bigen Hair Colour Medium Chestnut 47

Bigen Hair Colour Medium Chestnut 47

  • 1. Ozempic®️-equivalent therapy now available for weight management
  • 2. Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • 3. May help reduce osteoarthritis-related pain
  • 4. Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • 5. Supports cardiovascular risk reduction
  • 6. Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £3.99
Sale price £3.99 £3.69
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

Medium Chestnut permanent hair colour. Bigen Permanent Hair Color is suitable for those who want to achieve 100% gray coverage or to darken their natural hair color. Bigen permanent hair color is ammonia free and does not require hydrogen peroxide. The unique powder formula is activated by water to naturally open the hairs cuticle to deposit rich, natural color into even the most stubborn gray hair. This deposit only color is the gentle choice and has been proven for over thirty years. Bigen is the #1 selling permanent powder hair color. Bigen produces optimum darkening results regardless of your natural hair color, consistency, condition, length or style. (Box design may vary). All products will be shipped from the UK. Ingredients: SODIUM CARBONATE,CELLULOSE GUM, SODIUM CARBONATE PEROXIDE, p-PHENYLENEDIAMINE SULFATE, m-AMINOPHENOL SULFATE, XANTHAN GUM, p-METHYLAMINOPHENOL SULFATE, TRISODIUM HEDTA, DISODIUM LAURYL SULFOSUCCINATE, GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE,4-AMINO-2-HYDROXYTOLUENE SULFATE,MAGNESIUM STEARATE, PARFUM, ALGIN, SAPINDUS MUKUROSSI PEEL EXTRACT.

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2233073
Tarun Kumar

Reviewed by:

Tarun Kumar

Superintendent/ Clinical Lead

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities